advanced hepatocellular carcinoma with impaired liver function
Conditions
Interventions
deferoxamine
UFT
Sponsors
First Department of Internal Medicine, Yamaguchi University School of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Patients with advanced hepatocellular carcinoma 2) Non-responders for chemotherapy with anticancer drugs 3) Patients who have no influence on previous treatment 4) Performance status(PS) 0 or 1 5) Child-Pugh B 6) Favorable function of major organs (bone marrow, kidney, heart), and meeting citeria as follows: (1) WBC >= 2500/mm3 (2) platelet count>= 50000/mm3 (3) hemogrobin level >= 9.0g/dl (4) total bilirubin <= 3.0mg/dl (5) serum creatinine level < 2mg/dl (6) BUN <= 25mg/dl (7) prothrombin time activity >= 50% 7) age >= 20years, male and female
Exclusion criteria
Exclusion criteria: 1) Severe coexisting illness (expect for chronic hepatitis or liver cirrhosis) 2) Active bouble cancers 3) Past history of hypersensitivity for drugs including iodine and contrast agent 4) Patients with pregnancy, lactation or possibility of pregnancy 5) Past history of interstitial pneumonia 6) Chronic respiratory failure 7) Patients who judged as inadequacy due to other reasons by the doctor
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Survival | — |
Secondary
| Measure | Time frame |
|---|---|
| Response, Progression-free survival, Safety | — |
Countries
Japan
Outcome results
None listed